Glaukos Corporation (GKOS)
NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 96.84 |
| Open | 95.98 |
| Bid | 66.00 x 800 |
| Ask | 100.00 x 800 |
| Day's range | 95.79 - 98.36 |
| 52-week range | 45.38 - 102.33 |
| Volume | |
| Avg. volume | 685,387 |
| Market cap | 4.796B |
| Beta (5Y monthly) | 1.10 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.78 |
| Earnings date | 01 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 106.09 |
Business WireGlaukos Announces the Release of its 2023 Sustainability Report
ALISO VIEJO, Calif., April 16, 2024--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2023 Sustainability Report. The report highlights the company’s continued commitment and progress on its key corporate sustainability initiatives. The Sustainability Report can be found on the company’s website here.
ZacksHere's Why You Should Retain Glaukos (GKOS) Stock for Now
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
ZacksGlaukos (GKOS) Gains Nearly 25% YTD: What's Driving the Rally?
Glaukos' (GKOS) shares have risen year to date on the back of strong fundamentals. However, rising costs can be a cause of concern.
© 2024 Yahoo. All rights reserved.